Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EXOVIR INC. SELECTS FORMER B-W PRESIDENT SULLIVAN

Executive Summary

EXOVIR INC. SELECTS FORMER B-W PRESIDENT SULLIVAN to move the oral and genital herpes product HZ-Gel into the marketing-clearance stage. In a July 15 announcement of the selection of William Sullivan, 52, as president and CEO, the company said that the alpha interferon and nonoxynol-9 combo is in the final stages of clinical evaluation. Trials could be completed by the end of the summer. At Burroughs Wellcome, Sullivan held the top spot from from 1981 to 1986. During his presidency at B-W, the company introduced the first major antiviral product to the U.S. market, Zovirax (acyclovir) for treating genital herpes. Sullivan succeeds Richard Glaser, who is leaving the company, as Exovir's president. As chief exec, Sullivan is taking one of the titles previously held by Maxwell Powell, 71, who will remain chairman.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS012185

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel